Gilead needs a big R&D hit. Here's why claims on NASH fall well short of that

For months now, the pres­sure has been build­ing on Gilead to do some­thing dra­mat­ic on the R&D side of the busi­ness, with an­a­lysts clam­or­ing for the big biotech to buy some­thing or build some­thing big.

So when re­searchers claimed that they had hit pay dirt da­ta in a mid-stage study of GS-4997 for a block­buster in­di­ca­tion like NASH, the com­pa­ny built it up as en­cour­ag­ing proof of ef­fi­ca­cy and sig­nif­i­cant progress on an im­por­tant front.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.